Pre-made Sotrovimab benchmark antibody ( Whole mAb, anti-SARS-CoV-2 Spike RBD therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-530

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-530 Category Tag

Product Details

Pre-Made Sotrovimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Sotrovimab is an investigational monoclonal antibody therapy medication with activity against SARS-CoV-2. It is under development by GlaxoSmithKline and Vir Biotechnology, Inc.

Products Name (INN Index)

Pre-Made Sotrovimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody

INN Name

Sotrovimab

Target

SARS-CoV-2 Spike RBD

Format

Whole mAb

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Approved

Est. Status

Active

100% SI Structure

None

99% SI Structure

7jx3:AB/6ws6:EF/6wps:CD:FG:HL/6wpt:DE:HL

95-98% SI Structure

None

Year Proposed

2020

Companies

GlaxoSmithKline,Vir Biotechnology

Conditions Approved

COVID-19

Conditions Active

NA

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

SARS-CoV-2 Spike RBD

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide